Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical KB105 for TGM1-deficient ARCI
NCT05735158Phase 2Unknown
- Sponsor
- Krystal Biotech, Inc.
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autosomal recessive congenital ichthyosis (ARCI) comparing KB105 Target Area with Placebo Target Area (2 arms). Primary endpoint: Composite Investigator's Global Assessment (IGA) Responder at Week 9. Status: unknown.
02
Drugs
KB105
03
Conditions
autosomal recessive congenital ichthyosis (ARCI)
Beyond the preview
Go deeper on NCT05735158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735158.